Clinical Trials Logo

Clinical Trial Summary

A second botulism outbreak in Northern Thailand was reported in 2006. 192 people were exposed to raw meat and the gut of deer, 83 suffered from diarrhea. Of these 5 developed respiratory failure, 1 impending respiratory failure.

We analysed the clinical findings and electrophysiologic findings in this second episode of large botulism outbreak in northern Thailand.


Clinical Trial Description

PRELIMINARY REPORT Northern Thailand's big botulism outbreak occurred again on 30 June 14, 2006, [16.00pm] affecting 83 from 192 people who exposed to raw dear meat and gut [1 night preserved with ice pack of whole body of dear before disection and distribution ]. Of these, 3 developed respiratory failure, 1 developed impending respiratory failure, 83 of 192 whom developed fatique and diarrhea after ingestion of raw dear meat and gut on 26-30 June 2006. 3 patients were refered to 2 high facility hospitals for severe respiratory failure. Physical examination of 3 patients in ICU of Chiang Kum general hospital revealed ptosis [3/3] mild ophthalmoparesis [2/3] Proximal muscle weakness [2/3] abdominal paradoxical respiration [3/3] pupil dilate [1/3] and negative inspiratory pressure [NIP] less than 15 mmHg [3/3] were observed. Neurological electrophysiologic study of 2 patients revealed low amplitude compound muscle action potential [CMAP] of Abductor digiti minimi [ADM] muscle with decrement response after repetitive stimulation with low frequency [3Hz], increment response of ADM muscle after stimulation with high frequency [10Hz, 20Hz, and 30Hz.].The electrophysiologic findings support diagnosis of presynaptic neuromuscular dysfunction with respiratory failure, Botulism is most likely diagnosis. After treated with botulinum antitoxin [on July,1 ,2006 [mixed-type botulinum antitoxin --donated from Japan at Nan Hospital's botulisum outbreak on March 14,2006], 3 patients in ICU showed improvement of over all clinical outcomes. Active survey by Ministry of Public Health of Thailand and CDC-USA to identify the high risk patient who may develop respiratory failure , and immunologucal vs microbiological diagnosis were performed. This outbreak may be the second hit of botulisum in the northern Thailand but less amount of severe cases was observed. ;


Study Design

Observational Model: Defined Population, Time Perspective: Longitudinal


Related Conditions & MeSH terms


NCT number NCT00348426
Study type Observational
Source Rajavithi Hospital
Contact
Status Completed
Phase Phase 4
Start date June 2006
Completion date September 2006

See also
  Status Clinical Trial Phase
Completed NCT03603665 - A Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy Adults Phase 1
Not yet recruiting NCT04550793 - Using Shear Wave Ultrasound Elastography for Follow up After Anti-spastic Intervention Among Stroke Patients
Completed NCT01441557 - Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism Phase 2/Phase 3
Recruiting NCT05769478 - Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA Phase 1
Withdrawn NCT01940315 - Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B Phase 3
Enrolling by invitation NCT02051062 - BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients Phase 4
Completed NCT02055183 - BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin
Completed NCT01357213 - Phase 1 PK Study of XOMA 3AB Phase 1
Completed NCT03676634 - Tolerability and Immunogenicity of rBV A/B for the Production of BabyBIG® Phase 2
Completed NCT00314080 - Treatment of Survivors After Botulism Outbreak N/A
Not yet recruiting NCT06112834 - Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG® Phase 2
Completed NCT00004401 - Study of Human Botulism Immunoglobulin in Infants With Botulism N/A
Completed NCT01701999 - Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid Phase 2
Completed NCT02779140 - Phase I, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632 Phase 1